Key Findings:
In a recent study published in Cell Medicine, researchers explored the potential of combining electric field therapy with the immunotherapy drug pembrolizumab to improve treatment outcomes for patients with glioblastoma—an aggressive and treatment-resistant form of brain cancer. The study found that patients who received both electric field therapy and pembrolizumab experienced a significantly longer progression-free survival (PFS) compared to those treated with immunotherapy alone, all while maintaining manageable safety profiles. On a biological level, the electric field appeared to enhance immune system activity by boosting antigen presentation and promoting T-cell infiltration into tumors. This synergistic effect with pembrolizumab suggests that electric field therapy may help overcome immune resistance in glioblastoma, marking a promising advancement in the development of more effective treatment strategies.
